AP -- Genentech Inc.'s fourth-quarter profit rose 47 percent on sales of its blockbuster cancer drug Avastin, but the biotechnology company set a weaker-than-expected outlook for 2009. The results, reported late Thursday, come as the shadow of a potential buyout by part-owner Roche hangs over the company. That anticipation prompted Wall Street to view both positive and negative developments for the company through the prism of their ability to drive any new deal value.
